StreetAlpha.app
Home › Stocks › RIGL

Rigel Pharmaceuticals Inc (RIGL)

$40.09
▼ −2.67%
LAST CLOSE · NOV 20

Rigel is a South San Francisco biotechnology company that develops and sells medicines for blood disorders and cancer. It last closed at $40.09 on Nov 20, down 2.67% on the day. The next earnings report for RIGL is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, RIGL reported EPS of $0.65 on revenue of $80.9M, with revenue up 16.5% from a year ago. Over its last 8 reports the stock moved an average of 11.6% the session after earnings. Over the last 12 months RIGL insiders bought $0 of stock on the open market and sold $306K, according to SEC Form 4 filings.

AI Auto Pilots
Is RIGL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RIGL.

Key Stats

Last 12 months
Results
Revenue
$288.2M
+2.2% vs a year ago
Net income
$307.2M
+171.1% vs a year ago
EPS (diluted)
$16.07
+159.6% vs a year ago
Gross margin
89.6%
$258.3M gross profit
Valuation
Market cap
$754.9M
18.8M shares
P/E
2.5
Price over 12 month EPS
Price to sales
2.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$46.6M
At Sep 30
Shareholder equity
$445.1M
Shares outstanding
18.8M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $149.2M$149.2MFY2021FY2022: $120.2M$120.2MFY2022FY2023: $116.9M$116.9MFY2023FY2024: $179.3M$179.3MFY2024FY2025: $294.3M$294.3MFY2025

From RIGL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
$0.65
Quarter ended Sep 2026
Year ago EPS
$1.46
−55.5% on a GAAP basis
Revenue
$80.9M
+16.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.81Dec '24Mar 2025: $0.63Mar '25Jun 2025: $3.28Jun '25Sep 2025: $1.46Sep '25Dec 2025: $14.10Dec '25Mar 2026: $0.44Mar '26Jun 2026: $0.88Jun '26Sep 2026: $0.65Sep '26Latest $0.65
Revenue by quarter
Dec 2024: $57.6MDec '24Mar 2025: $53.3MMar '25Jun 2025: $101.7MJun '25Sep 2025: $69.5MSep '25Dec 2025: $69.8MDec '25Mar 2026: $58.8MMar '26Jun 2026: $78.7MJun '26Sep 2026: $80.9MSep '26Latest $80.9M
How RIGL moved after its last 8 reports
Average move the session after a report ±11.6%
Nov 5, 2026After the close−13.3%
Aug 4, 2026After the close+4.6%
May 5, 2026After the close−5.1%
Mar 3, 2026After the close−10.3%
Jan 12, 2026Time not announced−2.1%
Nov 4, 2025After the close+33.4%
Aug 5, 2025After the close+23.0%
May 6, 2025After the close+1.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RIGLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RIGL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RIGL

Technical Analysis

RIGL · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 15% below its 20 day and 17% below its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $39.25, and the nearest resistance the Pivot at $40.46.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.9%/day
Key levels
$52.6052 week high+31.2%
$46.9050 day average+17.0%
$46.0520 day average+14.9%
$44.72100 day average+11.5%
$43.34Swing high (Jul 16)+8.1%
$41.29Pivot R1+3.0%
$40.46Pivot+0.9%
$40.09Last close
$39.25Pivot S1−2.1%
$37.76200 day average−5.8%
$37.60Swing low (Nov 6)−6.2%
$24.9552 week low−37.8%
Indicators
RSI (14)35.07Weak, oversold below 30Neutral
MACD-1.71Below its signal lineBearish
Stochastic25.2Middle of its rangeNeutral
ADX (14)24.1Weak trend
Williams %R-82.4Oversold below −80, overbought above −20Oversold
CCI (20)-102.2Oversold below −100, overbought above 100Oversold
Rate of change+1.1%Change over 10 sessionsBullish
ATR (14)$2.35Typical daily range, 5.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for RIGL

What happened before

See how RIGL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RIGL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RIGL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RIGLHow many large options trades hit RIGL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

RIGL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲94 buying vs 67 selling
  • ▲Held by funds +12.4 pts
  • ▲Funds holding +13
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding170157+8.3%
In funds' top 1032+50.0%
Held by funds99.5%87.0%+12.4 pts
New / increased32 / 6232 / 52+11.9%
Reduced / sold out49 / 1856 / 26−18.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RIGL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RIGL Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$306K3 sales · 2 insiders
52% of the selling was under pre-arranged trading plans.
2026-02 sold $145K2026-05 sold $73K2026-06 sold $88KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 22Kamil Ali-JacksonDirectorSale plan2,500$35.00$88K
May 26Kamil Ali-JacksonDirectorSale plan2,500$29.17$73K
Feb 20Walter H MoosDirectorSale4,000$36.36$145K
Feb 5, 2025Raymond J. FureyEVP, GC, CCO & Corp SecSale2,787$21.41$60K
Feb 5, 2025Raul R RodriguezCEO, PresidentSale9,352$21.40$200K
Feb 5, 2025David A SantosEVP, Chief Commercial OfficerSale3,921$21.38$84K
Every insider buy and sale for RIGL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RIGL insider trades →

From SEC Form 4 filings by RIGL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RIGL is in one of them and how their past RIGL trades turned out.

RIGL in the AI portfolios
Loading…

RIGL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RIGL in an article yet. Here's the latest on the wider market.

RIGL in the news

About Rigel Pharmaceuticals

Rigel is a biotechnology company based in South San Francisco, California, that develops and sells medicines for patients with blood disorders and cancer. Its approved products include TAVALISSE, an oral medicine for adults with chronic immune thrombocytopenia, REZLIDHIA for certain adults with relapsed or refractory acute myeloid leukemia, and GAVRETO for certain lung and thyroid cancers. The company is also developing other treatments, including an experimental drug for a blood disorder called myelodysplastic syndrome.

Headquarters
South San Francisco, CA